TransMedics Q1 revenue $96.9M (+133% YoY), net income $12.2M; raises FY2024 revenue guide to $390-400M

TransMedics Group, Inc.

2024-Q1 EPS reported $0.35 revenue$96,850,000

Q1 net revenue $96.9M (+133% YoY); net income $12.2M ($0.35 diluted EPS) vs net loss $2.6M in Q1 2023.
Gross margin 62% (down from 69% YoY) due to higher service revenue mix; operating expenses $47.5M.
Cash balance $350.2M at March 31, 2024.
FY2024 revenue guidance raised to $390-400M (from $360-370M), representing 61-66% YoY growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

TransMedics Group, Inc. reported quarter ended March 31, 2024 results: revenue $96.9 million, net income $12.2 million, EPS $0.35 per fully diluted share. Guidance raised.

Period: quarter ended March 31, 2024
Revenue: $96.9 million
Net income: $12.2 million
EPS: $0.35 per fully diluted share
Guidance: raised
Result: reported results

Exact text from the filing

Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first quarter of 2023

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

TransMedics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-050568

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.